0000000000267259

AUTHOR

Jonathan Howlett

0000-0002-0535-9771

showing 2 related works from this author

Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction…

2019

Background Physicians’ adherence to guideline-recommended therapy is associated with short-term clinical outcomes in heart failure (HF) with reduced ejection fraction (HFrEF). However, its impact on longer-term outcomes is poorly documented. In this analysis we assessed the longer-term association of physicians’ adherence with clinical outcomes, including mortality and unplanned hospitalisations, at 18-month follow-up of the QUALIFY registry (Clinical trial registration ISRCTN87465420) Method and results Data at 18 months were available for 6118 ambulatory HFrEF patients from this international prospective observational survey. Adherence was measured as a continuous variable, ranging from 0…

Malemedicine.medical_specialtyDoseMedication Therapy ManagementHeart failureOutcomes030204 cardiovascular system & hematologyGuidelinesMedication03 medical and health sciences0302 clinical medicineDosageInternal medicineMedication therapy managementOutcome Assessment Health CareOutpatientsmedicineHumansRegistriesPractice Patterns Physicians'Heart FailureEjection fractionGuideline adherencebusiness.industryCardiovascular AgentsStroke VolumeStroke volumeMiddle Agedmedicine.diseaseQuality ImprovementConfidence intervalClinical trialHospitalizationAdherenceHeart failureCardiovascular agentAmbulatoryPractice Guidelines as TopicObservational studyFemaleGuideline AdherenceCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesEuropean journal of heart failure
researchProduct

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without typ…

2020

Abstract Aims The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF). Methods and results HF patients with reduced EF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or preserved EF (>40%, N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The …

medicine.medical_specialtyCardiomyopathyType 2 diabetes030204 cardiovascular system & hematologyPlacebo03 medical and health sciences0302 clinical medicineGlucosidesInternal medicinemedicineClinical endpointEmpagliflozinHumans030212 general & internal medicineBenzhydryl CompoundsHeart FailureEjection fractionSurrogate endpointbusiness.industryStroke Volumemedicine.diseaseDiabetes Mellitus Type 2Heart failureCardiologyCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct